retatrutide dosing trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II People always say my dose
Description
The FDA has raised concerns about unapproved GLP-1 drugs used for weight loss, including fraudulent compounded products, dosing errors, and adverse event reports involving compounded semaglutide and tirzepatide.
GLP-1 medications are recommended in the ADA Standards of Care for those with cardiovascular disease, heart failure, and/or kidney disease to reduce the risk of adverse events due to these conditions
On average, the highly efficacious second-generation GLP-1 drugs cost between $900 and $1,350 per month, not counting insurance or rebates
The dehydration hypothesis Clinical trial protocols strictly define medication adherence and dosing
Bagsvaerd, Denmark: Novo Nordisk
